Dabrafenib for treatment of BRAF-mutant melanoma

Radhika Kainthla, Kevin B. Kim, Gerald S. Falchook

Research output: Contribution to journalReview article

16 Scopus citations

Abstract

Melanoma has the highest mortality of all the skin cancer subtypes. Historically, chemotherapy and immunologic therapies have yielded only modest results in the treatment of metastatic melanoma. The discovery of prevalent V600 BRAF mutations driving proliferation makes this oncogenic protein an ideal target for therapy. Dabrafenib, a reversible inhibitor of mutant BRAF kinase, improved response rates and median progression-free survival in patients with V600E BRAF-mutant metastatic melanoma, including those with brain metastases. With a well-tolerated toxicity profile, dabrafenib is effective as a monotherapy; however, resistance eventually develops in almost all patients. As a result, current research is exploring the role of combination therapies with dabrafenib to overcome resistance.

Original languageEnglish (US)
Pages (from-to)21-29
Number of pages9
JournalPharmacogenomics and Personalized Medicine
Volume7
Issue number1
DOIs
StatePublished - Dec 31 2013

    Fingerprint

Keywords

  • Dabrafenib
  • Metastatic melanoma
  • V600E BRAF mutation

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this